Dr Contreras questioned the decision of Medicines Division to include a statement in commercial plasma packaging that products have been tested for ALT. Argued "screening plasma donations for ALT is totally absurd since any hypothetical benefit obtained by excluding donations with high ALT is lost by pooling".